Drug Ads Should Take A Long View, DDMAC Says In Citing Time-To-Onset Claims
This article was originally published in The Pink Sheet Daily
FDA sends notice of violation letters to Dow Pharmaceutical Sciences (Valeant) and Novartis for stretching a point in promotional materials for Acanya Gel and Focalin XR, respectively.
You may also be interested in...
FDA says Valiant’s webpage for Zovirax overstates the efficacy of the herpes drug and makes unsubstantiated claims it is superior to Valtrex. It is the fifth letter the agency has sent the company in the past year.
A clever marketing graphic is dinged because it comes in the context of unjustified superiority claims.
The first warning letter of the year from FDA’s Office of Prescription Drug Promotion goes to Teva for web pages and materials displayed at a medical conference that overstated the safety and efficacy of its MS drug Copaxone.